The telehealth companies Hims & Hers and Noom launched peptide brands this week. Neither launched with any of the six peptides the federal government said three weeks ago it would let pharmacies compound. Both say BPC-157 and TB-500 may come later.
Noom announced OpenRx on November 17, 2026, and Hims & Hers announced Peptides+ the next day. Both offer prescriptions after a clinical visit, filled by compounding pharmacies. On October 30, the Department of Health and Human Services published a notice about compounding. It said the department will not act against licensed pharmacies and physicians compounding BPC-157, TB-500, KPV, MOTS-c, epitalon and semax under stated conditions, while FDA decides by rule whether to add them to the 503A bulks list.
The launches are the market's first large answer to that notice, and the answer is careful. Every peptide the two companies chose to sell first already had a footing in FDA's record before October 30, as the active ingredient of an approved drug or as a substance in FDA's Category 1. The six that the notice covers, and that the policy debate has been about, are on neither company's launch list.
What Hims & Hers and Noom launched
Hims & Hers said that after a visit with a licensed provider, customers may be prescribed up to five treatments at launch: Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine
. Its release adds: Access to BPC-157 and TB-500 will follow, consistent with regulatory standards.
The company says the products are compounded in the United States and dispensed by licensed pharmacies regulated by state boards of pharmacy
.
Noom's OpenRx offers sermorelin and NAD+ by vial, and two dissolvable tablets: one combining PT-141 and oxytocin with tadalafil, and one of oxytocin alone. The company says prescriptions are filled through its accredited 503A pharmacy network
. Its chief medical officer, Jeffrey Egler, said the company is currently reviewing BPC-157 and TB-500 as part of our ongoing process of evaluating emerging treatments for inclusion in our formulary
.
Of the ingredients the two companies list, four are peptides: sermorelin, oxytocin, PT-141 and glutathione, a three-amino-acid peptide. NAD+, vitamin B12 and L-carnitine are not peptides.
The FDA record behind each launch peptide
Section 503A lets a pharmacy compound from a bulk substance that has a pharmacopeia monograph, is a component of an FDA-approved drug, or is on the 503A bulks list. While FDA builds that list, its interim policy says it does not intend to act against compounding from substances in its Category 1. Each launch ingredient that is a peptide, and NAD, has a documented place in that framework that the six HHS peptides do not:
| Ingredient | FDA record |
|---|---|
| Oxytocin | Active ingredient of an approved drug (Pitocin, NDA 018261, approved 1980) |
| PT-141 (bremelanotide) | Active ingredient of an approved drug (Vyleesi, NDA 210557, approved June 21, 2019) |
| Sermorelin | Active ingredient of a formerly approved drug (Geref, NDAs 019863 and 020443, discontinued); FDA determined in 2013 it was not withdrawn for reasons of safety or effectiveness |
| Glutathione | FDA Category 1, list of May 14, 2026 |
| NAD | FDA Category 1, list of May 14, 2026 |
| BPC-157, TB-500, KPV, MOTS-c, epitalon, semax | Not on the 503A bulks list; covered only by the HHS enforcement-discretion notice of October 30, 2026 |
Whether each launch product meets every other condition of section 503A is not something either release shows, and this table does not claim it. What it shows is a choice. Both companies began with the peptides whose status rests on an approval or on FDA's own interim policy, and set aside the six whose status rests on a notice that does not establish any rights for any person and is not binding on HHS or the public
. FDA's Category 2 peptide list and research peptides vs compounded peptides explain the framework.
Why two telehealth companies might wait on BPC-157
Neither company has said why the six were not ready at launch, and there is more than one explanation consistent with the record.
One is supply. The HHS notice attaches conditions to the bulk peptide itself: according to counsel who have read the policy, a manufacturer registered with FDA and operating under good manufacturing practice, named on a certificate of analysis that covers identity, impurities, endotoxin and more. A national pharmacy network needs a qualified source for each peptide before it can compound at scale, and that takes time. Hims & Hers' phrase, consistent with regulatory standards
, fits that reading.
The other is risk. The notice binds no state, and Alabama, Mississippi and South Carolina have told their licensees that under no circumstances is it permissible
to compound or dispense a research-grade peptide. On November 9 the American Medical Association adopted policy urging HHS to rescind the notice and committing to work with state boards on swift enforcement actions
against compounding pharmacies and direct-to-consumer telehealth platforms
, among others. Our piece on the AMA sets out its directives. A company prescribing in many states at once has more exposure to state boards than a single clinic does.
The notice also carries its own exit. HHS says it may revisit application of this interim policy (in whole or in part) if, among other things, a safety signal or product quality issue arises
. A company that builds a product line on the six accepts that the federal footing under it can be withdrawn by the same department that laid it, without a rule and without notice beyond the department's word.
The two explanations are not exclusive, and both lead to the same place: the peptides that prompted the policy are, for now, a promise on the largest telehealth platforms rather than a product.
The companies' case for compounded peptides
Both companies present their launches as an improvement on what came before. Hims & Hers says that until now, getting such medications has often meant relying on unreliable and unregulated online sellers, or a high-cost longevity clinic
, and that its model adds a licensed provider, regular follow-up and pharmacies regulated by state boards. Noom says every prescription follows an evaluation of the patient's health history, goals, and clinical appropriateness
and that its pharmacy network adheres to USP compounding standards
.
That is the same argument the Alliance for Pharmacy Compounding made for the HHS notice on October 28: that a supervised, documented channel is better than the one it replaces. It is the argument the AMA rejects, on the ground that no channel can supply evidence of safety and efficacy that does not yet exist.
What to watch after the telehealth peptide launches
- The first BPC-157 or TB-500 listing. When either company adds the six, and whether it says which manufacturers and which states.
- State boards. Whether any board acts on a telehealth prescription for the six, as the AMA has asked them to.
- The final HHS policy. Whether the notice, now past its comment period, is kept, changed or withdrawn, which will decide whether the six arrive at all.
- FDA rulemaking. Only a final rule adding the six to the 503A bulks list would put them on the same footing as the launch peptides.
Frequently asked questions
- Do Hims & Hers and Noom sell BPC-157?
- Not at launch. Hims & Hers says access to BPC-157 and TB-500
will follow, consistent with regulatory standards
. Noom says it iscurrently reviewing BPC-157 and TB-500
. - What peptides did Hims & Hers and Noom launch with?
- Hims & Hers listed sermorelin, NAD+, glutathione, vitamin B12 and L-carnitine. Noom's OpenRx listed sermorelin, NAD+, a tablet of PT-141 and oxytocin with tadalafil, and an oxytocin tablet.
- Why didn't they launch with the six HHS peptides?
- Neither company has said. The launch peptides already had a footing in FDA's record, as approved-drug ingredients or in FDA's Category 1; the six rely on an October 2026 enforcement-discretion notice that binds no state. Sourcing ingredients that meet the notice's conditions may also take time.
- Are compounded peptides from telehealth companies FDA-approved?
- No. Compounded drugs are not FDA-approved; section 503A exempts them from approval when its conditions are met. This is not legal advice.
Sources & Further Reading
- Hims & Hers Health, Inc. Hims & Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health. Press release, November 18, 2026.
- Noom. Noom Launches OpenRx, a New Peptide and Preventive Health Brand. Press release, Princeton, NJ, November 17, 2026, noom.com.
- Food and Drug Administration. Drugs@FDA application records via openFDA: NDA 018261 (Pitocin, oxytocin); NDA 210557 (Vyleesi, bremelanotide); NDAs 019863 and 020443 (Geref, sermorelin acetate). Read November 21, 2026.
- Food and Drug Administration.
Determination That GEREF (Sermorelin Acetate) Injection
was not withdrawn from sale for reasons of safety or effectiveness. FR Doc. 2013-04827, March 4, 2013. - Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list), May 14, 2026.
- Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances; notice of availability. 91 FR 68526, October 30, 2026.
- American Medical Association. Highlights from the 2026 AMA Interim Meeting, ama-assn.org.
- Alliance for Pharmacy Compounding. Statement from Scott Brunner, CEO, October 28, 2026.
See also
- FDA decides whether a research peptide is an illegal drug from what its seller says, and no court reviews the call
- Eli Lilly has sued 11 sellers of retatrutide, its unapproved experimental peptide, and no court has ruled yet
- The cheapest research-peptide sellers are the ones that vanish, and their certificates of analysis vanish with them
- Coroner finds prescribed, compounded peptides caused Australia's first confirmed peptide death, of stunt coordinator Richard Norton
- House defense bill would stop the Pentagon listing "legally available peptides" as banned for troops
- Health Canada finds bacteria in a peptide seized in Ottawa and says research labels change nothing
- American Medical Association calls on HHS to rescind its peptide compounding policy and on states to enforce
- Most comments on the HHS peptide policy are one form letter seeking three peptides FDA advisers rejected
- Louisiana bars boards from blocking peptide compounding that meets federal law. The six HHS peptides do not yet meet it.
- HHS cleared six peptides for compounding. Three states forbid their doctors to prescribe them.
- U.S. sets ten conditions for pharmacies to compound six unapproved peptides, with 14 days to comment
- U.S. health secretary overrules FDA to let pharmacies compound six unapproved peptides
- Our products are not designed for humans. Our brand is.
- FDA's Category 2 peptide list now names one peptide for pharmacies, kisspeptin-10, after 17 withdrawals — article
- Research peptides vs compounded peptides: one is a lab chemical, the other a prescription drug from a pharmacy — article
- Compounded drug — glossary
- FDA Category 2 — glossary
- 503A bulks list — glossary
- Enforcement discretion — glossary
Cite this page
Text
Cosmic Peptides. (2026, November 21). Hims & Hers and Noom launch peptide brands without any of the six peptides HHS cleared. Cosmic Peptides Research Library. Retrieved November 21, 2026, from https://cosmicpeptides.com/research/perspectives/telehealth-peptide-launches
BibTeX
@misc{cosmicpeptides_research_perspectives_telehealth_peptide_launches,
author = {{Cosmic Peptides}},
title = {Hims \& Hers and Noom launch peptide brands without any of the six peptides HHS cleared},
howpublished = {Cosmic Peptides Research Library},
year = {2026},
month = nov,
url = {https://cosmicpeptides.com/research/perspectives/telehealth-peptide-launches},
urldate = {2026-11-21},
note = {Last reviewed 2026-11-21}
} RIS
TY - ELEC AU - Cosmic Peptides TI - Hims & Hers and Noom launch peptide brands without any of the six peptides HHS cleared T2 - Cosmic Peptides Research Library PB - Cosmic Peptides PY - 2026 DA - 2026/11/21 UR - https://cosmicpeptides.com/research/perspectives/telehealth-peptide-launches Y2 - 2026/11/21 LA - en ER -
Cite the date the page was last reviewed, November 21, 2026, as its version. Reference managers such as Zotero can save this page directly.
Changes to this page
- Published Hims & Hers and Noom launch peptide brands without any of the six peptides HHS cleared
Opinion: Noom's OpenRx (November 17, 2026) and Hims & Hers' Peptides+ (November 18) launched without any of the six peptides in the HHS enforcement-discretion notice; the FDA record behind each launch peptide (Drugs@FDA, the 2013 Geref determination, Category 1); supply and risk as reasons to wait; the companies' case. The companies are named with the owner's approval.
Changes of substance are listed here; wording changes are not. Every correction is also on the corrections log.
For in vitro laboratory research only. Not for human or veterinary use. This library describes chemistry, analytical methods and published laboratory research; it gives no guidance on use in people or animals.